From: news-medical.net SCIENTISTS in Salford, UK, have identified a gene which is ‘revving the engine of cancer’ against the world’s most common breast cancer drug. For reasons unknown, 50% of patients with breast cancer treated with the estrogen receptor-blocking drug tamoxifen eventually become resistant to the treatment. In a paper published this week in the journal Oncotarget, biochemists tested a …
New drug delivery system shows promise for fighting solid tumors
A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiation treatment. Carcinomas that affect the breast, lung, prostate and colon are among these solid-tumor cancers, as are malignancies in the lymphatic system, known as lymphomas, and the much less common sarcomas that arise in …
Don’t Blame Patients for Getting Cancer
View PostLBBC Receives Leadership Sponsorship from Lilly for its Innovative Metastatic Breast Cancer Programs
Living Beyond Breast Cancer (LBBC) announced today that Eli Lilly and Company is providing a Leadership level sponsorship to support its innovative metastatic breast cancer programs, in particular its Hear My Voice Metastatic Breast Cancer Outreach Program, which was created to address the educational and support needs of women and men living with metastatic breast cancer (MBC). The sponsorship will …
Getting Assistance With Your Cancer Medications
View PostYale Study Published in JNCCN Uncovers Racial Disparities in Treatment of Women with Breast Cancer
In a simple definition, cancer is a disease of the cells, which is caused by gene mutations. For a proportion of patients, including women with hormone receptor positive (HR+) breast cancer, gene expression profiling has a substantial impact on treatment decision-making by determining which patients might—or might not—respond to particular treatment options. Gene expression profiling tests are readily available, yet …
Cota Healthcare Announces Major Multi-Year Collaboration With Global Pharmaceutical Leader To Advance Innovative Therapies For Breast Cancer Patients
Cota Healthcare, the leading data and technology platform for value-based precision medicine, today announced the signing of a major, multi-year collaboration with Novartis Pharmaceuticals Corporation to help improve clinical and cost outcomes for breast cancer patients. As part of this agreement, which expands significantly on the previous announced collaboration entered into January 2016, teams from across Novartis Pharmaceuticals Corporation will …
Legislation Will Interfere With Cancer Drug Payment Assistance
View PostOld-Style Chemo Is Still A Mainstay In The Age Of Targeted Cancer Therapy
By: Richard Harris From: npr.org Chemotherapy remains one of the mainstays of cancer treatment, but these harsh drugs are slowly being edged aside in medical research, as new treatments, like immunotherapy, grab the spotlight. Still, this is not the end of the road for chemotherapy. For one thing, doctors are coming to realize that some of these drugs are useful …
When it comes to breast cancer treatment, is a double mastectomy a good idea?
By: Elli Jacobs From: smh.com.au In 2013, Renee Gani, then 36, received the news every woman dreads. “Being large-busted, I always had a habit of checking myself,” she says. “I found a lump in my right breast and waited for a week hoping it would disappear.” But a biopsy confirmed it was indeed breast cancer. “My immediate thought was to …